Company research
EyePoint, Inc.
CIK 1314102Updated Sep 24, 2026
SecurityEYPT · NASDAQ · equity
Name history
EyePoint Pharmaceuticals, Inc. · through Dec 8, 2025pSivida Corp. · through Mar 30, 2018pSivida LTD · through Jun 18, 2008
EYPT price & chart
Loading TradingView…
NASDAQ:EYPT on TradingView ↗About the company
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT ↗
Recent filings
Other Events
Items 8.01, 9.01
4 filing
Other Events
Items 8.01, 9.01
SCHEDULE 13G/A filing
SCHEDULE 13G filing
Show 5 more recent filings
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G filing
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 363,996,000Source | 418,465,000Source | 355,184,000Source | 180,356,000Source |
| Property, Plant and Equipment, NetUSD | 9,023,000Source | 8,177,000Source | 5,251,000Source | 1,360,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 101,821,000Source | 99,704,000Source | 281,263,000Source | 95,633,000Source |
| Inventory, NetUSD | 1,813,000Source | 2,305,000Source | 3,906,000Source | 2,886,000Source |
| Assets, CurrentUSD | 328,655,000Source | 383,306,000Source | 344,800,000Source | 172,808,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 20,105,000Source | 9,481,000Source | 9,039,000Source | 9,858,000Source |
| Operating Lease, Right-of-Use AssetUSD | 20,223,000Source | 21,000,000Source | 4,983,000Source | 6,038,000Source |
| Other Assets, NoncurrentUSD | 5,945,000Source | 5,832,000Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 57,883,000Source | 81,964,000Source | 88,861,000Source | 83,988,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 83,000Source | 68,000Source | 49,000Source | 34,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,104,978,000Source | -873,016,000Source | -742,146,000Source | -671,351,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 961,000Source | 1,028,000Source | 864,000Source | 786,000Source |
| Stockholders' Equity Attributable to ParentUSD | 306,113,000Source | 336,501,000Source | 266,323,000Source | 96,368,000Source |
| Additional Paid in Capital, Common StockUSD | 1,410,047,000Source | 1,208,421,000Source | 1,007,556,000Source | 766,899,000Source |
| Liabilities and EquityUSD | 363,996,000Source | 418,465,000Source | 355,184,000Source | 180,356,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 37,024,000Source | 49,048,000Source | 63,263,000Source | 34,537,000Source |
| Operating Lease, Liability, CurrentUSD | 2,022,000Source | 1,247,000Source | 563,000Source | 543,000Source |
| Accounts Payable, CurrentUSD | 10,490,000Source | 11,721,000Source | 6,504,000Source | 5,919,000Source |
| Operating Lease, Liability, NoncurrentUSD | 20,772,000Source | 21,858,000Source | 4,906,000Source | 5,984,000Source |
| Other Liabilities, NoncurrentUSD | 87,000Source | 205,000Source | — | 600,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 24,394,000Source | 18,103,000Source | 17,521,000Source | 16,359,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 306,100,000Source | 370,900,000Source | 331,000,000Source | 144,600,000Source |
| Deferred Revenue, CurrentUSD | 0Source | 17,784,000Source | 38,592,000Source | 1,205,000Source |
| Deferred Revenue, NoncurrentUSD | 0Source | 10,853,000Source | 20,692,000Source | 13,557,000Source |
| Long-term DebtUSD | — | — | — | 30,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | 29,310,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -231,962,000Source | -130,870,000Source | -70,795,000Source | -102,254,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,309,000Source | 1,540,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 27,873,000Source | 36,740,000Source | 12,057,000Source | 14,177,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | -492,000Source | -1,600,000Source | 1,553,000Source | 760,000Source |
| Deferred Income Tax Expense (Benefit)USD | 279,000Source | 90,000Source | 83,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -240,110,000Source | -126,226,000Source | 1,875,000Source | -65,005,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 68,580,000Source | -219,355,000Source | -3,315,000Source | -17,265,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 3,280,000Source | 4,052,000Source | 3,483,000Source | 2,150,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 1,388,000Source | 4,512,000Source | 169,000Source | 295,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 173,647,000Source | 164,022,000Source | 187,070,000Source | -690,000Source |
| Repayments of Long-term DebtUSD | — | 0Source | 30,000,000Source | 38,235,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 2,117,000Source | -181,559,000Source | 185,630,000Source | -82,960,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 101,971,000Source | 99,854,000Source | 281,413,000Source | 95,783,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 0Source | 1,405,000Source | 2,600,000Source |
| Income Taxes Paid, NetUSD | 200,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 27,873,000Source | 36,740,000Source | 12,057,000Source | 14,177,000Source |
| Amortization of Intangible AssetsUSD | — | — | 0Source | 2,050,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 306,100,000Source | 370,900,000Source | 331,000,000Source | 144,600,000Source |
| DepreciationUSD | 2,100,000Source | 1,540,000Source | 464,000Source | 396,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | 0Source | -1,347,000Source | -1,559,000Source |
| General and Administrative ExpenseUSD | 51,610,000Source | 52,358,000Source | 40,102,000Source | 34,817,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 0Source | 20,699,000Source |
| Income Tax Expense (Benefit)USD | 279,000Source | 90,000Source | 83,000Source | 0Source |
| InterestExpenseNonoperatingUSD | 33,000Source | 14,000Source | — | — |
| Inventory Write-downUSD | — | 0Source | 693,000Source | 1,949,000Source |
| Net Income (Loss) Attributable to ParentUSD | -231,962,000Source | -130,870,000Source | -70,795,000Source | -102,254,000Source |
| Nonoperating Income (Expense)USD | 11,751,000Source | 15,074,000Source | 4,355,000Source | -2,617,000Source |
| Operating ExpensesUSD | 274,805,000Source | 189,127,000Source | 121,085,000Source | 141,041,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 1,200,000Source |
| Other Nonoperating Income (Expense)USD | 11,784,000Source | 15,088,000Source | 6,949,000Source | 2,131,000Source |
| Proceeds from Issuance of Common StockUSD | 173,445,000Source | 163,314,000Source | 226,174,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | 0Source | 30,000,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | 124,000,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 395,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 31,371,000Source | 43,273,000Source | 46,018,000Source | 41,404,000Source |
| Operating Income (Loss)USD | -243,434,000Source | -145,854,000Source | -75,067,000Source | -99,637,000Source |
| Other Nonoperating Income (Expense)USD | 11,784,000Source | 15,088,000Source | 6,949,000Source | 2,131,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -231,683,000Source | -130,780,000Source | -70,712,000Source | -102,254,000Source |
| Income Tax Expense (Benefit)USD | 279,000Source | 90,000Source | 83,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -231,962,000Source | -130,870,000Source | -70,795,000Source | -102,254,000Source |
| Earnings Per Share, BasicUSD per share | -3.17Source | -2.32Source | -1.82Source | -2.74Source |
| Earnings Per Share, DilutedUSD per share | -3.17Source | -2.32Source | -1.82Source | -2.74Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 73,251Source | 56,298Source | 38,904,000Source | 37,317,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 73,251Source | 56,298Source | 38,904,000Source | 37,317,000Source |
| Interest Expense (non-operating)USD | 33,000Source | 14,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 0Source | 2,050,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,309,000Source | 1,540,000Source | — | — |
| General and Administrative ExpenseUSD | 51,610,000Source | 52,358,000Source | 40,102,000Source | 34,817,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -231,783,000Source | -130,880,000Source | -70,812,000Source | -102,354,000Source |
| Interest ExpenseUSD | — | — | 1,247,000Source | 3,189,000Source |
| Nonoperating Income (Expense)USD | 11,751,000Source | 15,074,000Source | 4,355,000Source | -2,617,000Source |
| Operating ExpensesUSD | 274,805,000Source | 189,127,000Source | 121,085,000Source | 141,041,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 1,200,000Source |
| Research and Development ExpenseUSD | 221,039,000Source | 132,926,000Source | 64,662,000Source | 49,642,000Source |
| Selling and Marketing ExpenseUSD | 90,000Source | 131,000Source | 11,689,000Source | 25,507,000Source |
Filing attachments
eypt-ex99_1.htm · 8-K · 2026-09-10
EX-99.1 2 eypt-ex99_1.htm EX-99.1 LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses | September 2026 Exhibit 99.1 Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or bel…
Read attachment ↗eypt-ex99_1.htm · 8-K · 2026-08-17
EX-99.1 2 eypt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYUTM 2.7mg in Wet AMD - DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD; primary endpoint not achieved in full dataset, confounded by this asymmetric cohort - …
Read attachment ↗eypt-ex99_2.htm · 8-K · 2026-08-17
EX-99.2 3 eypt-ex99_2.htm EX-99.2 LUGANO Phase 3 Clinical Trial Topline Results DURAVYU in Wet AMD August 17, 2026 Exhibit 99.2 Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occu…
Read attachment ↗eypt-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 eypt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments - Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 - - - Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 - - - Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 - - - $180 mill…
Read attachment ↗eypt-ex99_2.htm · 8-K · 2026-08-05
EX-99.2 3 eypt-ex99_2.htm EX-99.2 Investor Presentation August 2026 Exhibit 99.2 Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, are forward-looking statements…
Read attachment ↗eypt-ex99_1.htm · 8-K · 2026-07-30
EX-99.1 2 eypt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME) - COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients - - - Topline 56-week data for both DME trials anticipated in 4Q 2027 - WATERTOWN, Mass., July 30, 2026 (GLOBE NEWSWIRE) - …
Read attachment ↗